Balyasny Asset Management’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
Other funds holding CTKB
Balyasny Asset Management's CTKB Position: Q3 2026 in Review
Balyasny Asset Management sold out of Cytek Biosciences (CTKB) in Q3 2026, closing a stake of 54,381 shares — an estimated $241K sold.
Balyasny Asset Management first reported a position in CTKB in Q4 2022 and held it in 8 quarters. The position peaked at $1.26M in Q4 2022. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.
- Balyasny Asset Management reported no remaining Cytek Biosciences position as of Q3 2026 after selling out during the quarter.
- Balyasny Asset Management sold 54,381 Cytek Biosciences shares in Q3 2026, an estimated $241K.
- Balyasny Asset Management first reported a position in Cytek Biosciences in Q4 2022 and held it in 8 quarters.
- Balyasny Asset Management's Cytek Biosciences position peaked at $1.26M in Q4 2022.
- 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.